22 results
6-K
MREO
Mereo Biopharma Group Plc
10 Nov 22
Current report (foreign)
4:06pm
and the audit committee independence requirements of Rule 10A-3 of the Securities Exchange Act of 1934, as amended.
There are no arrangements
6-K
MREO
Mereo Biopharma Group Plc
26 May 22
Current report (foreign)
4:11pm
Global Market listing requirements and the audit committee independence requirements of Rule 10A-3 of the Securities Exchange Act of 1934, as amended
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
the “independence” requirements set forth in Rule 10A-3 under the Exchange Act. The Audit and Risk Committee is governed by a charter that complies with Nasdaq … the auditor is engaged to render such services;
evaluating the independent auditor’s qualifications, performance and independence, and presenting
F-4
EX-10.8
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
on their skills, experience, knowledge and, where appropriate, independence;
develop productive working relationships with all executive directors and the Chief
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
, Mr. Rosen does not meet the rigorous criteria we look for in potential director candidates, including independence and deep and recent executive
10-K
sqqdk sdxwlx
27 Mar 24
Annual report
5:20pm
20-F
4t6it5qv2m4
29 Apr 19
Annual report (foreign)
4:59pm
F-1/A
cheye0 il0
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
F-1/A
ez2a9 wydw
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
S-3
EX-1.2
shkoofv
15 May 24
Shelf registration
4:49pm
F-3
EX-1.2
0sai aqdop1qj4
5 Aug 21
Shelf registration (foreign)
4:33pm
425
o3tw95ps7d4t
6 Dec 18
Business combination disclosure
2:26pm
424B5
71hnbn8dry
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
25zrqv5v d2y0eqr
6 Oct 20
Shelf registration (foreign)
4:25pm
424B5
q7xrrg7 v8y8jj0g
9 Feb 21
Prospectus supplement for primary offering
5:24pm
424B5
nbvkbf
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B3
dm973 cn303ksfefw
20 Mar 19
Prospectus supplement
4:58pm